CCM
SWTX

CAAS Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

CAAS Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-112,643
Closed -$7.15M – 1038
2021
Q3 		$7.15M Buy
+112,643
New +$8.68M 0.14% 152
2021
Q2 		– Sell
-224,886
Closed -$16.5M – 1269
2021
Q1 		$16.5M Buy
224,886
+90,364
+67% +$7.08M 0.18% 132
2020
Q4 		$9.76M Buy
+134,522
New +$8.66M 0.09% 210

Other funds holding SWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAAS Capital Management's SWTX Position: Q4 2021 in Review

CAAS Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q4 2021, closing a stake of 112,643 shares — an estimated $7.15M sold.

CAAS Capital Management first reported a position in SWTX in Q4 2020 and held it in 3 quarters. The position peaked at $16.5M in Q1 2021. 144 funds tracked by Wall St. Rank hold SWTX as of Q4 2021.

  • CAAS Capital Management reported no remaining SpringWorks Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 112,643 SpringWorks Therapeutics shares in Q4 2021, an estimated $7.15M.
  • CAAS Capital Management first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 3 quarters.
  • CAAS Capital Management's SpringWorks Therapeutics position peaked at $16.5M in Q1 2021.
  • 144 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.